Ranbaxy’s $500 Million GMP Settlement Would Be Second Most Expensive For Rx Manufacturing Violations
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy Laboratories said it has signed a consent decree with FDA and set aside $500 million to settle a related Department of Justice investigation involving GMP violations and data integrity issues at its Indian facilities.
You may also be interested in...
Generic Lipitor Era Dawns With Watson’s Launch, Followed By Ranbaxy’s Last-minute Approval
Teva will share in Ranbaxy’s profits during its exclusivity period, as FDA announces approval of Ranbaxy’s first-filed ANDA more than 14 hours after Watson discloses that it began shipping its atorvastatin “authorized generic”.
GSK’s $750 Mil. DoJ Settlement: When GMP Violations Equal Healthcare Fraud
GlaxoSmithKline’s $750 million settlement with the Department of Justice raises a worrisome question for industry: will violations of current good manufacturing practices become a target for whistleblower suits?
Schering NDAs Are Clear For Review Under FDA Consent Decree
Schering-Plough NDAs will not be subject to extra scrutiny under the GMP consent decree with FDA